Department of General and Oncologic Surgery, University of Perugia, Perugia, Italy
World J Surg Oncol. 2012 Jul 30;10:155. doi: 10.1186/1477-7819-10-155.
BRAF inhibitors such as vemurafenib are a new family of biological drugs, recently available to treat metastatic malignant melanoma.
We present the case of a 38-year-old man affected by metastatic melanoma who had been under treatment with vemurafenib for a few days. The patient suffered from sudden onset of abdominal pain due to intra-abdominal hemorrhage with profuse hemoperitoneum. An emergency abdominal sonography confirmed the clinical suspicion of a splenic rupture.
The intraoperative finding was hemoperitoneum due to splenic two-step rupture and splenectomy was therefore performed. Histopathology confirmed splenic hematoma and capsule laceration, in the absence of metastasis.
This report describes the occurrence of a previously unreported adverse event in a patient with stage IV melanoma receiving vemurafenib.
BRAF 抑制剂（如维莫非尼）是一类新型的生物药物，最近被用于治疗转移性恶性黑色素瘤。
我们报告了一例接受维莫非尼治疗数天的转移性黑色素瘤 38 岁男性患者的病例。该患者因腹腔内出血导致大量血腹而突发腹痛。急诊腹部超声证实了脾破裂的临床诊断。
术中发现因脾两步破裂导致的血腹，因此行脾切除术。组织病理学证实为脾血肿和包膜裂伤，但无转移。
本报告描述了一例接受维莫非尼治疗的 IV 期黑色素瘤患者发生的一种先前未报道的不良反应。
